Generic Name and Formulations:
Atovaquone 750mg/5mL; oral susp; citrus flavor.
Indications for MEPRON:
Treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in patients intolerant to trimethoprim/sulfamethoxazole (TMP/SMX). Prevention of PCP in patients intolerant to TMP/SMX.
Limitations Of use:
Treatment of more severe PCP has not been studied. Mepron's efficacy has not been studied in those who are failing therapy with TMP/SMX.
Take with food. ≥13yrs: Treatment: 750mg twice daily for 21 days. Prophylaxis: 1500mg once daily.
<13yrs: not established.
GI disorders or inability to take with food. Monitor in severe hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant rifampin or rifabutin: not recommended. Antagonized by tetracycline; caution and monitor if use is needed. May be antagonized by metoclopramide (use only if other antiemetics are not available). Antagonizes indinavir; caution and monitor if use is needed.
Diarrhea, rash, headache, nausea, fever, rhinitis, vomiting, sweating, flu syndrome, sinusitis, pruritus, insomnia, depression, myalgia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC